Astrazeneca office in Mölndal, Sweden, on September 12, 2024.
Norfuto Gety pictures
Astrazeneca On Tuesday, CEO Pascal Soriot reiterated the pharmaceutical company’s commitment to the American market amid reports that he is considering changing the United States list.
Soreriot said that the UK listed company has many reasons why it is in the United States, adding that it was “transmitting rapid manufacturing” across the Atlantic so that it could serve all the needs of the American patient locally.
“We have a lot of reasons for being here (in the United States),” Soreriot told the media during the profit call.
He added: “This country (the United States) will represent, we hope, 50 % of our revenues by 2030. We have thousands of employees … all over the country.”
Astrazneca has doubled in the United States market, saying in its profit report in the second quarter on Tuesday that the country was a key to its ambition to achieve $ 80 billion revenues by the end of the contract.
“We are a global company, but we are certainly very present and rooted in the United States,” Soreriot said, noting that it plans to become self -sufficiency soon there.
The company said last week that it is planning Invest 50 billion dollars In strengthening its capabilities to manufacture and research in the United States. It represents the latest pharmaceutical company to increase its spending in the United States in the wake of the American commercial tariffs and the calls of President Donald Trump to re -manufacture.
“Our investments reflect our belief in the growth of this country. We want to contribute to this,” Soreriot said.
He added: “The United States is really leading the vital pharmaceutical innovation these days.” “Today, very little comes out of Europe.”
Action attack?
Astrazneca, which has been changing international newspapers by developing one of the main Covid-19 vaccines, gives priority to the American market. The United States formed more than 40 % of the company’s annual revenue in 2024.
Earlier this month, the Times stated that the company may transfer its list from London to the United States, while analysts said it would be a Hoop To the public markets in the United Kingdom.
Astrazeneca refused at the time to comment on the report. However, Aradhana Sarin said on Tuesday that the company is still “committed” to the United Kingdom
This comes at a time when Astrazeneca recorded better profits than expected in the second quarter on Tuesday, driven by demand for basic cancer and biological pharmaceutical products.
Anglo -Sweden drugs achieved revenues of $ 14.46 billion during the three -month period until June 30, 14.07 billion dollars, estimated by analysts in the LSEG survey.
The basic basic operation profit reached 4.58 billion dollars, for an expected $ 4.48 billion.
FTSE 100 has maintained its expectations for the entire year because of its high percentage of revenues from one percentage and basic profits per share to increase a low percentage.
It comes at a time when the European pharmaceutical sector is facing The expected fees of 15 % On imports to the United States as part of a broader trade deal for the European Union. Analysts have warned that the customs tariff, if imposed by 15 % or more, could hinder European companies and the broader economy of the mass.
However, Astrazneca suggested in April that it will maintain sales guidelines for 2025 if the American definitions of European drug products are in line with those imposed against other sectors.
“This issue of definitions is not really a problem that affects us a lot,” Soreriot said.
https://image.cnbcfm.com/api/v1/image/108178200-1753768619531-gettyimages-2171601095-romano-astrazen240912_np42i.jpeg?v=1753768650&w=1920&h=1080
Source link